Risk Reduction in Coronary Heart Disease

NACompletedINTERVENTIONAL
Enrollment

1,600

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
Coronary Heart Disease
Interventions
BEHAVIORAL

smoking cessation

NRT and varenicline

DRUG

betablocker, diuretics, ACEI, ARB,

blood pressure control according to ESC guidelines

DRUG

statins, ezetimibe

Cholesterol reduction according to ESC guidelines

BEHAVIORAL

training

daily walking

BIOLOGICAL

influenza vaccine

vaccine (FLuarix, Influvac etc)

DRUG

metformin, glimepiride, insulin

s.glucose control according to ESC guidelines

BEHAVIORAL

weight reduction

diet tips

Trial Locations (1)

Unknown

Sorlandet Hospital, Arendal

All Listed Sponsors
collaborator

Oslo University Hospital

OTHER

lead

Sorlandet Hospital HF

OTHER_GOV

NCT00679237 - Risk Reduction in Coronary Heart Disease | Biotech Hunter | Biotech Hunter